Point-Counterpoint: US FDA Adcomm Joint Briefing Document Likely Limited To Oncology For Now

 
• By Sue Sutter
  
Debate podiums
There are differences of opinion on use of a joint FDA-sponsor briefing document for advisory committee meetings. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers